1689P - Cachexia in pancreatic cancers. Comparison of adenocarcinoma and neuroendocrine tumors

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Neuroendocrine Cancers
Supportive Care
Pancreatic Cancer
Presenter Mohandas Mallath
Authors M.K. Mallath, A. Yelsengekar, S. Mehta, P.S. Patil
  • Digestive Diseases, Tata Memorial Hospital Centre, 400012 - Mumbai/IN

Abstract

Background

Patients with pancreatic adenocarcinoma (pCA) have high propensity for weight loss and cachexia. Patients with pancreatic neuroendocrine tumors (pNET) maintain their muscle mass for long period of time. Aims: We undertook a study to quantify the magnitude of cachexia in patients with pNET and compare it with pCA.

Methods

An audit of the nutrition clinic database from 2000 to 2011 was reviewed and identified patients with pNET or pCA who had full nutritional work up including subjective global assessment scores (SGA) and body mass index (BMI). Cachexia was defined as a SGC score = C or BMI <18.5 Kg/M2. Cachexia and other variables of pNET patients were compared with pCA.

Results

There were 328 pCA patients and 88 pNET patients. There were 286 males and 130 females with age ranging from 11 to 95 years (Mean 53 years for pCA and 48 pNET; p = 0.003). The SGA score were A= 39.5%; B= 55.3%; C= 5.3% in pNET group and A= 12.7%; B= 52.5%; C= 34.8% in pAC group. BMI below 18.5 was significantly higher in the pCA group. Malnutrition (SGA B + C) and Cachexia were significantly associated with pCA. Odds ratio for Cachexia in pNET subjects after adjusting for age and sex was 0.249 (p = 0.0009). Cachexia was absent in several pNET patients with multiple liver metastases. pNET patients developing cachexia had high grade tumors with MIB-1 score over 20%.

Conclusions

Patients with pNET are resistant to cancer cachexia while those with pCA are highly susceptible to cancer cachexia. Further research on the biochemical and molecular pathways will help to understand cancer cachexia in pancreatic cancers.

Disclosure

M.K. Mallath: Participated as an investigator or coinvestigator in clinical trials sponsored by the following pharmaceutical companies: Amgen Inc, Astra Zeneca, Bayer, Bristol Mayer Squibb, Glaxo Smith Kline, ISPEN Pharma, Merck, Pfizer, Roche, Sanofi S.A. Mehta: Participated as an investigator or coinvestigator in clinical trials sponsored by the following pharmaceutical companies: Amgen Inc, Astra Zeneca, Bayer, Bristol Mayer Squibb, Glaxo Smith Kline, ISPEN Pharma, Merck, Pfizer, Roche, Sanofi, P.S. Patil: Participated as an investigator or coinvestigator in clinical trials sponsored by the following pharmaceutical companies: Amgen Inc, Astra Zeneca, Bayer, Bristol Mayer Squibb, Glaxo Smith Kline, ISPEN Pharma, Merck, Pfizer, Roche, Sanofi, All other authors have declared no conflicts of interest.